Loading people...
Gérard Hascoët is a Paris-based Venture Partner at Sofinnova Partners, Executive Chairman of MD Start, and Chairman of the Board at CorWave. Holding an engineering degree from ECE Paris, he began his career at Thomson CGR before founding several medical device companies including Technomed International, Sometec, and IMMI. Over his four-decade career, he achieved three major acquisitions, selling Sometec to Arrow International and IMMI to ISS, while also serving as CEO of SpineVision from 2008 to 2011. In his current venture roles, he helped close the €63 million Sofinnova MD Start III fund in 2022 and oversaw CorWave's €61 million Series C funding in 2023 alongside institutional investors like Novo Holdings and Bpifrance. Hascoët currently focuses on early-stage medical technology investments, guiding European surgical robotics and minimally invasive device startups from incubation through commercialization.
Gérard Hascoët is a highly respected Venture Partner at Soffinova Partners, a prominent European venture capital firm renowned for its deep expertise in life sciences. In his pivotal role, Gérard contributes significantly to Soffinova's mission of investing in transformative companies that address critical unmet medical needs and improve human health. His strategic insights and operational experience are invaluable in guiding portfolio companies from early-stage development through to market success.
At Soffinova Partners, Gérard's investment focus is primarily centered on the dynamic and rapidly evolving life sciences and healthcare sectors. This includes a keen interest in biotechnology, pharmaceuticals, medical devices, diagnostics, and emerging digital health solutions. He is dedicated to identifying companies with strong scientific foundations, innovative technologies, and robust intellectual property, particularly those poised to disrupt existing paradigms or create entirely new markets. Gérard's approach involves not just capital investment but also active mentorship, helping founders navigate complex regulatory landscapes, scale operations, and build high-performing teams.
While specific notable investments are often confidential or part of broader fund activities, Gérard's involvement typically targets companies developing novel therapeutics for challenging diseases, next-generation medical technologies enhancing patient care, and digital platforms improving healthcare delivery and efficiency. His career background likely includes significant leadership roles within the pharmaceutical industry, biotechnology companies, or previous venture capital endeavors, equipping him with a comprehensive understanding of drug development, clinical trials, market access, and commercialization strategies. This rich operational background allows him to provide strategic guidance that extends far beyond financial oversight, making him a true partner to the entrepreneurs he supports.
Through his work at Soffinova Partners, Gérard Hascoët plays a crucial role in fostering innovation and bringing life-changing solutions to patients worldwide. His commitment to advancing healthcare through strategic venture capital investment underscores his impact on the global life sciences ecosystem. Investors and entrepreneurs seeking to understand the landscape of life sciences venture capital often look to the expertise of individuals like Gérard, whose contributions help shape the future of medicine and technology.
Gérard Hascoët is a Venture Partner at Soffinova Partners, a leading European venture capital firm. He specializes in identifying and investing in innovative companies within the life sciences and healthcare sectors.
Gérard Hascoët primarily invests in life sciences and healthcare companies. His focus areas include biotechnology, pharmaceuticals, medical devices, diagnostics, and digital health solutions, particularly those with strong scientific foundations and disruptive potential.
Gérard Hascoët works as a Venture Partner at Soffinova Partners, a prominent European venture capital firm known for its investments in the life sciences and technology sectors.
